20453 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
METHODS FOR TREATING EARLY ALZHEIMER’S DISEASE
#2PAPD5 INHIBITORS AND METHODS OF USE THEREOF
#3CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
#4COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
#5METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
#6COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
#7USE OF SMALL-MOLECULE COMPOUND HAVING NAPHTHYLAMINE STRUCTURE
#8AZAQUINAZOLINE PAN-KRAS INHIBITORS
#9HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5-MTA AND USE THEREOF
#10BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION
#11CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER
#12METHODS OF LOCAL IRRIGATION FOR TREATING INFECTIONS
#13NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE
#14PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#15MODULATION OF BACE1 AS A THERAPY FOR SPINOCEREBELLAR ATAXIA
#16COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
#17METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME
#18Improved Synthesis of Taurolidine, Purity Profiles and Polymorphs
#19QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
#20METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
#21PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
#22COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
#23MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT
#24CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION
#25TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES
#26SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE
#27METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
#28METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD
#29PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
#30THIADIAZINE DERIVATIVES
#31Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#32RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions
#33TRICYCLIC SULFAMIDES AND SULTAMS
#34SMALL-MOLECULE COMPOUND HAVING NAPHTHALENETHIOL ETHER STRUCTURE, AND USE THEREOF
#35NOVEL INHIBITOR OF HYPE-MEDIATED AMPYLATION
#36TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR
#37COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
#38PHOSPHODIESTERASE 3 (PDE3) INHIBITORS
#39APPLICATION OF ATP POTASSIUM CHANNEL MODIFIER IN PREPARATION OF ANTI-DIABETIC NEPHROPATHY DRUG
#40TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS
#41SUSTAINED RELEASE FORMULATIONS COMPRISING A SELECTIVE ANDROGEN RECEPTOR MODULATOR
#42SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#43METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#44Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#45ANTIMICROBIAL AND ANTICANCER AGENTS
#46PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION
#47BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION
#48CO-PROCESSED PRE-FORMULATED EXCIPIENT COMPOSITION FOR POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
#49ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION
#50Solid forms and methods of preparing the same
#51COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER
#52COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT
#53Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#54NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS
#55Compositions for the treatment of hypertension
#56TREATMENT FOR DEPRESSION
#57QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
#58BACE1 INHIBITOR TREATMENT FOR SUPPRESSING CYTOKINE STORM
#59COMPOSITIONS OF EDTA HAVING ACTIVITY AGAINST PLANKTONIC AND BIOFILM CELLS OF CLINICALLY RELEVANT PATHOGENS
#60PHARMACEUTICAL COMBINATION COMPRISING A BRAIN AMINOPEPTIDASE A INHIBITOR, A DIURETIC AND A BLOCKER OF THE SYSTEMIC RENIN-ANGIOTENSIN SYSTEM
#61METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY
#62THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION
#63COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAME
#64MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE
#65USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER
#66ANTIVIRAL AGENT
#67Hydrochlorothiazide compositions
#68Particle Coating Method
#69SOFT CHEWABLE FORMED BODY FOR THE ADMINISTRATION TO ANIMALS
#70Therapeutics for the treatment of glaucoma
#71COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER
#72Particle Coating Method
#73Compositions for the treatment of hypertension
#74METHOD TO PREVENT AND TREAT MACULAR DEGENERATION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
#75DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF
#76ORAL PHARMACEUTICAL COMPOSITION COMPRISING A MELT-AGGLOMERATED ACTIVE INGREDIENT CORE
#77COMBINATION THERAPY FOR TREATING OR PREVENTING SKIN DAMAGE
#78THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOMA AND OTHER CANCERS
#79SKIN-PENETRATING FORMULATION OF TAUROLIDINE
#80QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
#81PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#82METHODS AND COMPOSITIONS FOR INHIBITING GAPDH
#83Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
#84METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
#85INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION
#86PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS
#87HYDROCHLOROTHIAZIDE COMPOSITIONS
#88COMPOUNDS AND METHODS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (PKD)
#89Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
#90Salts of potassium ATP channel openers and uses thereof
#91LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER
#92TLR8 agonist
#93Solid forms and methods of preparing the same
#94COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
#95UTILIZATION OF ENDOGENOUS OUBAIN-REGULATING COMPOUNDS AND COMPOSITIONS THEREOF IN TREATMENT OF VASCULAR DISEASE
#96COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
#97METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
#98METHOD TO PREVENT AND TREAT GINGIVAL RECESSION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
#99METHOD TO PREVENT AND TREAT OCULAR CATARACT BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS
#100Preeclampsia biomarkers and related systems and methods
#101High-throughput automation of organoids for identifying therapeutic strategies
#102Method to prevent and treat macular degeneration by calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers
#10317beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
#104Thiadiazine derivatives
#105IMMUNE CHECKPOINT THERAPY
#106Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#107Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
#108PAPD5 inhibitors and methods of use thereof
#109Platform drug delivery system utilizing crystal engineering and theanine dissolution
#110Isoquinolines as inhibitors of HPK1
#111Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
#112NOVEL CHRONOTHERAPY BASED ON CIRCADIAN RHYTHMS
#113TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM
#114GASTRORETENTIVE FORMULATIONS
#115SKIN-PENETRATING FORMULATION OF TAUROLIDINE
#116DELIVERY OF ACTIVE AGENTS USING NANOFIBER WEBS
#117BACE1 inhibition for the treatment of cancer
#118METHODS FOR PREVENTION AND TREATMENT OF UROGENITAL ATROPHY OF MENOPAUSE BY CONTACT VASODILATORS
#119METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#120Therapeutics for the treatment of glaucoma
#121METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY
#122Compositions for the treatment of hypertension
#123DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF
#124ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION
#125Kinase inhibitor compounds and compositions and methods of use
#126FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION
#127Gastroretentive formulations
#128PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS
#129Quinazolines as potassium ion channel inhibitors
#130PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#131Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
#132Salts of potassium ATP channel openers and uses thereof
#133THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
#134Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#135Small molecule modulators of human sting
#136DISPENSING CAP CONTAINING A SOLUBILISATE OF A PHARMACEUTICALLY ACTIVE AGENT OR DIETARY SUPPLEMENT
#137Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
#138Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
#139DELIVERY OF ACTIVE AGENTS USING NANOFIBER WEBS
#140METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#141Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#142TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES
#143Neuroblastoma treatment with taurolidine hydrolysis products
#144METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
#145UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS
#146Adenosine A3 receptor modulators
#147IMMUNE CHECKPOINT THERAPY
#148Pyridyl-triazabicycles
#149Compositions for the treatment of hypertension
#150ANTIMICROBIAL COMBINATIONS
#151COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
#152Pharmaceutical composition comprising epidithiodioxopiperazine compound or derivative thereof, or pharmaceutically acceptable salt thereof, for preventing or treating pulmonary hypertension
#153Low dose immune checkpoint blockade in metastatic cancer
#154Antifungal composition
#155COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
#156PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING KELOIDS, HYPERTROPHIC SCARS AND WOUNDS, AND FOR PROVIDING IMPROVED SKIN CARE
#157Methods and pharmaceutical compositions for treating candida auris in blood
#158Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
#159Compounds and methods for kinase modulation, and indications therefor
#160Amino compounds for treatment of complement mediated disorders
#161Quinazolines as potassium ion channel inhibitors
#162FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA
#163Methods to treat neurodegenerative diseases
#164SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#165Risperidone biodegradable implant
#166Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#167Method of treating triple negative breast cancer
#168Phosphonate compounds for treatment of complement mediated disorders
#169Pharmaceutical composition for treatment of cancer using phenothiazine
#170Ether compounds for treatment of complement mediated disorders
#171Compounds for treatment of complement mediated disorders
#172Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
#173Orexin receptor antagonists
#174Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system
#175Solid forms and methods of preparing the same
#176Alkyne Compounds for Treatment of Complement Mediated Disorders
#177ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
#178ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
#179ISOQUINOLINES AS INHIBITORS OF HPK1
#180PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
#181Modulators of the adenosine A3 receptors
#182Compositions and methods for modulating FMR1 expression
#183Compositions for the treatment of hypertension
#184USE OF AN INJECTABLE ANTIMICROBIAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF OSTEOARTHRITIS
#1852-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS
#186Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders
#187Compositions for the treatment of hypertension
#1889-OH-risperidone controlled release composition
#189Heteroaryls and uses thereof
#190Compounds and methods for the treatment of neurodegenerative diseases
#191SKIN-PENETRATING FORMULATION OF TAUROLIDINE
#192Treating or preventing nephrogenic diabetes insipidus
#193SWEETENER COMPOSITION
#194ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
#195Carbazole-containing sulfonamides as cryptochrome modulators
#196NOVEL CHRONOTHERAPY BASED ON CIRCADIAN RHYTHMS
#197PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
#198Pharmaceutical for prophylaxis or treatment of hypertension
#199Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
#200Quinazolines as potassium ion channel inhibitors
#201Compounds for treatment of complement mediated disorders
#202Ether compounds for treatment of complement mediated disorders
#203Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
#204Fixed Dose Combination for Pain Relief Without Edema
#205Drug-containing PLA implants and methods of use thereof
#206Drug-containing implants and methods of use thereof
#207COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
#208Combination long acting compositions and methods for Hepatitis C
#209Long Acting Pharmaceutical Compositions For Hepatitis C
#210NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION
#211Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
#212Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
#213Amide compounds for treatment of complement mediated disorders
#214UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS
#215Methods to treat neurodegenerative diseases
#216Low dose immune checkpoint blockade in metastatic cancer
#217Methods of use and combinations
#218C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
#219TREATMENTS OF HEPATITIS C VIRUS INFECTION
#220Small molecule anti-scarring agents
#221Oxathiazine derivatives as antibacterial and anticancer agents
#222THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOMA AND OTHER CANCERS
#223Amino compounds for treatment of complement mediated disorders
#224NAT10 modulators for treating or preventing laminopathies, aging and cancer
#225METHOD FOR TEST ON DIABETIC NEPHROPATHY
#226Salts of potassium ATP channel openers and uses thereof
#227Metoprolol sustained-release composition and preparation method thereof
#228SKIN-PENETRATING FORMULATION OF TAUROLIDINE
#229Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile
#230Heteroaryls and uses thereof
#231COMPOSITIONS FOR THE TREATMENT OF JOINTS
#232Compounds for the treatment of medical disorders
#233Compounds and methods for kinase modulation, and indications therefor
#234DELIVERY OF ACTIVE AGENTS USING NANOFIBER WEBS
#235Methods and compositions for treating nephrogenic diabetes insipidus
#236Inhibition of hypoxia-inducible factor activity with carica papaya extracts
#237Therapeutics for the treatment of glaucoma
#238Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
#239Treating or preventing nephrogenic diabetes insipidus
#240Amide compounds for treatment of complement mediated disorders
#241Quinazolines as potassium ion channel inhibitors
#242Drug-containing implants and methods of use thereof
#243COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
#244ANTIBODIES THAT BIND TO HUMAN TAU AND ASSAY FOR QUANTIFYING HUMAN TAU USING THE ANTIBODIES
#245Modulators of intracellular chloride concentration for treating down syndrome
#246ORAL PHARMACEUTICAL FORM FOR PREVENTING VASCULAR DISEASES, TABLET AS PHARMACEUTICAL FORM AND GELATIN CAPSULE AS PHARMACEUTICAL FORM
#247Platform drug delivery system utilizing crystal engineering and theanine dissolution
#248Platform drug delivery system utilizing crystal engineering and theanine dissolution
#249Platform drug delivery system utilizing crystal engineering and theanine dissolution
#250METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS
#251METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#252Identification of small molecules that facilitate therapeutic exon skipping
#253COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS
#254Orexin receptor antagonists
#255PHARMACEUTICAL FOR PROPHYLAXIS OR TREATMENT OF HYPERTENSION
#256Carbazole-containing sulfonamides as cryptochrome modulators
#257Compounds and methods for kinase modulation, and indications therefor
#258Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
#259Solid Dosage Form of Olmesartan Medoxomil and Amlodipine
#260Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
#261MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
#262INJECTABLE COMPOSITION CONTAINING CHLOROTHIAZIDE
#263Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
#264Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
#265Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
#266Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
#267Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
#268TREATMENTS OF HEPATITIS C VIRUS INFECTION
#269COMBINATION THERAPEUTIC COMPOSITION
#270CYCLIC AMIDE DERIVATIVE
#271Phosphonate compounds for treatment of complement mediated disorders
#272Ether compounds for treatment of complement mediated disorders
#273Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
#274Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
#275Amino compounds for treatment of complement mediated disorders
#276Amide compounds for treatment of complement mediated disorders
#277Alkyne compounds for treatment of complement mediated disorders
#278Compounds for treatment of complement mediated disorders
#279Factor D inhibitors useful for treating inflammatory disorders
#280SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS
#281Heteroaryls and uses thereof
#282CYCLIC AMIDE DERIVATIVE
#283NEW DIFFERENTIAL-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE PRINCIPLES
#284Methods to treat neurodegenerative diseases
#285Pharmaceutical composition containing fimasartan and hydrochlorothiazide
#286Compositions and methods for the treatment of metabolic syndrome
#2875,6-dihydro-1H-pyridin-2-one compounds
#288Therapy for complications of diabetes
#289Solid compositions
#290Salts of potassium ATP channel openers and uses thereof
#291METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
#292Hetero-bicyclic derivatives as HCV inhibitors
#293COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS
#294Pharmaceutical formulations of potassium ATP channel openers and uses thereof
#295Risperidone-containing implants and methods of use thereof
#296Inhibiting G protein coupled receptor 6 kinase polypeptides
#297QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
#298METHOD FOR REGULATING SKIN PIGMENTATION
#299Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
#300Inhibition of hypoxia-inducible factor activity with extracts